<DOC>
	<DOCNO>NCT00420199</DOCNO>
	<brief_summary>The trial participant methotrexate-inadequate responder active Rheumatoid Arthritis , gadolinium-enhanced Magnetic Resonance Imaging ; Bone Mineral Density ; biochemical marker bone , cartilage , synovial tissue metabolism use evaluate early effect ( 4 month ) Abatacept inflammation/structural damage . Study provide valuable mechanism-of-action information Abatacept exert effect ( include bone ) new technique .</brief_summary>
	<brief_title>A Phase IIIb Study BMS-188667 Subjects With Active Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Disease activity define Disease Activity Score 28CReactive Protein ( CRP ) &gt; 3.2 &gt; 6 swollen â‰¥6 tender joint CRP great upper limit normal At least 1 erosion hands/wrists positive anticyclic citrullinated peptide rheumatoid factor Clinically detectable synovitis least 1 wrist/ankle screen baseline Participants must treat methotrexate , weekly dose least 15 mg maximum tolerate dose ( , 10 mg weekly ) least 3 month screen . Dose methotrexate must stable least 28 day prior first study dose ( Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>